LDL-adsorption ameliorates drug-resistant nephrotic syndrome due to focal glomerulosclerosis.

Yashiro, Masatomo; Muso, Eri; Matsushima, Munehiro; Nagura, Ryouichi; Sawanishi, K

doi:10.4009/jsdt1985.25.1363

Journal of Japanese Society for Dialysis Therapy

1992

DOI: 10.4009/jsdt1985.25.1363

|View full text |Cite

LDL-adsorption ameliorates drug-resistant nephrotic syndrome due to focal glomerulosclerosis.

Masatomo Yashiro¹,

Eri Muso²,

Munehiro Matsushima³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2002

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An apolipoprotein has been suggested as the circulating pathogenic factor (3). Alternatively, low‐density lipoprotein (LDL) is known to impair glomeruli, and LDL apheresis is sometimes effective in steroid‐resistant FSGS (4–10). However, the efficacy of LDL apheresis has not been compared with other modes of apheresis.…”

mentioning

confidence: 99%

Rapid and Persistent Reduction of Proteinuria Following Plasma Exchange in a Case of Steroid‐Resistant Focal Segmental Glomerulosclerosis

Ishii

Ando

Tamba

et al. 2002

Therapeutic Apheresis

View full text Add to dashboard Cite

We report on the case of a 45 year old male with focal segmental glomerulosclerosis (FSGS) in whom steroid-resistant proteinuria was reduced rapidly by plasma exchange. In 1994, he was admitted to our hospital because of massive proteinuria of several years' duration. Renal biopsy confirmed the diagnosis of FSGS. Proteinuria was suppressed partially with the use of dipyridamole. Though oral prednisolone (PSL, 30 mg/day) was effective initially, relapse occurred during PSL tapering. Doses of PSL up to 30 mg/day or additional mizoribine were ineffective. The patient was readmitted for a trial of plasma exchange in April 2000. Four sessions of plasma exchange with albumin replacement over 2 weeks immediately reduced the proteinuria from 3.2 g/day to 0.6 g/day without any change in medication. After discharge, proteinuria remained suppressed for more than 6 months despite a reduction of PSL dose to 15 mg. The rapid and long lasting effect of plasma exchange in the present case argues for the role of a putative circulatory factor in the pathogenesis of proteinuria in FSGS.

show abstract

mentioning

confidence: 99%

Rapid and Persistent Reduction of Proteinuria Following Plasma Exchange in a Case of Steroid‐Resistant Focal Segmental Glomerulosclerosis

Ishii

Ando

Tamba

et al. 2002

Therapeutic Apheresis

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

LDL-adsorption ameliorates drug-resistant nephrotic syndrome due to focal glomerulosclerosis.

Cited by 1 publication

References 0 publications

Rapid and Persistent Reduction of Proteinuria Following Plasma Exchange in a Case of Steroid‐Resistant Focal Segmental Glomerulosclerosis

Rapid and Persistent Reduction of Proteinuria Following Plasma Exchange in a Case of Steroid‐Resistant Focal Segmental Glomerulosclerosis

Contact Info

Product

Resources

About